Evidence map›Paper›PMID 42593572›Full record

ArticleWorld journal of urology2026

Positive surgical margins after partial nephrectomy across changing surgical eras: long-term oncological results from a tertiary referral center.

Alessandro Bertini, Chiara Re, Lucia Salerno, Giacomo Musso, Francesco Cei, Giuseppe Rosiello, Attilio Barretta, Federico Belladelli, Ciro Piccolo, Natasha Disabato and 14 more

Abstract read
PubMed Publisher
In one paragraph

Article in World journal of urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Alessandro BertiniDepartment of Urology and Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Urological Research Institute (URI), Milan, Italy. Bertini.alessandro@hsr.it.
Chiara ReDepartment of Urology and Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Urological Research Institute (URI), Milan, Italy.
Lucia SalernoDepartment of Urology and Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Urological Research Institute (URI), Milan, Italy.
Giacomo MussoDepartment of Urology and Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Urological Research Institute (URI), Milan, Italy.
Francesco CeiDepartment of Urology and Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Urological Research Institute (URI), Milan, Italy.
Giuseppe RosielloDepartment of Urology and Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Urological Research Institute (URI), Milan, Italy.
Attilio BarrettaDepartment of Urology and Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Urological Research Institute (URI), Milan, Italy.
Federico BelladelliDepartment of Urology and Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Urological Research Institute (URI), Milan, Italy.
Ciro PiccoloDepartment of Urology and Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Urological Research Institute (URI), Milan, Italy.
Natasha DisabatoDepartment of Urology and Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Urological Research Institute (URI), Milan, Italy.
Aurora CampugianiUniversity Vita-Salute San Raffaele, Milan, Italy.
Martina MontesanoUniversity Vita-Salute San Raffaele, Milan, Italy.
Gaetano FicarraUniversity Vita-Salute San Raffaele, Milan, Italy.
Nazario TenaceDepartment of Pathology, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Maurizio ColecchiaDepartment of Pathology, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Maurilio PonzoniDepartment of Pathology, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Antonio CigliolaDepartment of Medical Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Andrea NecchiUniversity Vita-Salute San Raffaele, Milan, Italy.
Alberto BrigantiDepartment of Urology and Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Urological Research Institute (URI), Milan, Italy.
Roberto BertiniDepartment of Urology and Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Urological Research Institute (URI), Milan, Italy.
Andrea SaloniaDepartment of Urology and Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Urological Research Institute (URI), Milan, Italy.
Francesco MontorsiDepartment of Urology and Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Urological Research Institute (URI), Milan, Italy.
Alessandro LarcherDepartment of Urology and Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Urological Research Institute (URI), Milan, Italy.
Umberto CapitanioDepartment of Urology and Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Urological Research Institute (URI), Milan, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeto reassess the prognostic value of positive surgical margins (PSM) after partial nephrectomy (PN) in terms of relapse-free survival (RFS), progression-free survival (PFS), overall survival (OS) and cancer-specific mortality (CSM) within a large cohort spanning changing surgical eras, including the progressive adoption of minimally invasive approaches. MATERIALS AND

methodsWe retrospectively analyzed 1441 patients who underwent PN for cM0 renal tumors between 2000 and 2024 at a tertiary referral center. Patients were stratified according to margin status (PSM vs. negative surgical margins, NSM). Kaplan-Meier analyses estimated RFS, PFS, and OS, while uni (UVA)- and multivariable (MVA) Cox regression models stratified by surgical era (2000-2011 vs. 2012-2024) tested the association between PSM and local relapse, progression, and all-cause mortality. Fine-Gray regression tested PSM impact on CSM. Then, exploratory interaction and subgroup analyses according to surgical approach were also performed.

resultsOf 1441 included patients, 81 (5.6%) had PSM on final pathology. Apart from a higher proportion of females in the PSM group (42% vs. 31%, p = 0.03), no clinical or pathological differences were observed between PSM and NSM (all p > 0.1). At 5-year follow-up, RFS, PFS, and OS were 90.5% vs. 96.7% (p = 0.003), 94.9% vs. 94.4% (p = 0.7), and 91.3% versus 94.4% (p = 0.1) for PSM vs. NSM, respectively. After adjustment for the selected clinical variables, PSM were associated with higher hazard of local relapse (HR: 4.03, 95% CI: 1.64-9.87; p = 0.002). No statistically significant association was observed between PSM and systemic progression (HR: 1.15, 95% CI: 0.35-3.74; p = 0.8), all-cause mortality (HR: 1.96, 95% CI: 0.82-4.72; p = 0.1), or CSM on Fine-Gray analysis (SHR: 2.66, 95% CI: 0.58-12.1, p = 0.2). However, the number of progression and mortality events in the PSM group was limited, resulting in wide CIs.

conclusionsPSM after PN were independently associated with a higher risk of local recurrence. No statistically significant association was observed with systemic progression, CSM, or OS; however, these analyses were limited by the small number of events, and clinically meaningful effects cannot be excluded. These findings support careful postoperative surveillance while larger contemporary studies are needed to better define the long-term prognostic impact of PSM.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsMargins of ExcisionNephrectomyAgedFemaleHumansMaleMiddle AgedNeoplasm Recurrence, LocalPrognosisRetrospective StudiesSurvival RateTertiary Care CentersTime FactorsKidney cancerMinimally invasive surgeryOncological outcomesPartial nephrectomyPositive surgical margins

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.